

Peripheral and Central Nervous System Drugs Advisory Committee Meeting
March 30, 2022
Pre-recorded Presentations

Both the Food and Drug Administration (FDA) and Amylyx Pharmaceuticals, Inc. have prepared pre-recorded presentations for the March 30, 2022 Peripheral and Central Nervous System Drugs Advisory Committee meeting. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day.**

The recordings of the presentations can be found at the following addresses:

FDA Presentations (listed in viewing order):

1. Clinical Overview: AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO)) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Veneeta Tandon, PhD; Division of Neurology 1 (1 of 2) - <https://collaboration.fda.gov/povzvaecetrd/>
2. Statistical Overview: AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO)) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Tristan Massie, PhD; Division of Neurology 1 (2 of 2) - <https://collaboration.fda.gov/pctw70a6h2y0/>

Amylyx Pharmaceuticals, Inc. Presentations:

1. AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Amylyx Pharmaceuticals, Inc. (1 of 1) – <https://collaboration.fda.gov/p84i2fmxbhob/>

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at:
<https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/march-30-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting>